Product brands of Guangdong Guoyitang Pharmaceutical Co., Ltd.

Guoyitang Culture

Chinese medicinal materials are the basis for preparing Chinese medicine pieces; Chinese medicine pieces are an important link in the production of Chinese medicine preparations; the stability of Chinese medicine quality depends on the quality of the Chinese medicine pieces. Guoyitang Pharmaceutical has long produced a large number of various types of Chinese patent medicines and is deeply aware of the impact of uneven quality of medicinal materials on the quality of Chinese medicines.

There has been no unified standard for the production of traditional Chinese medicinal materials and traditional Chinese medicine pieces in China for a long time. To this end, the State Food and Drug Administration requires GMP transformation and certification for the production of traditional Chinese medicine pieces, which will ensure the quality of traditional Chinese medicines.

The climate, geography, and environment of Guoyitang Pharmaceutical’s Guangdong production base are very favorable, and are very suitable for the production of real estate medicinal materials. After many inspections and demonstrations by traditional Chinese medicine experts, it is recommended to give full play to local advantages and use precious geothermal resources to carry out the planting, breeding and processing of traditional Chinese medicines and establish a unique medicine source base. With the support of the local government, the first batch of 200 acres of provenance base has been approved by the government for purchase. To this end, it jointly invested with the National Traditional Chinese Medicine Group to establish Guangdong Guoyitang Medicinal Source Base Co., Ltd., and worked closely with the local drug regulatory and agricultural authorities. The management departments jointly promote the industrial management of traditional Chinese medicines, which will contribute to exploring and formulating unified standards for the production of traditional Chinese medicines and Chinese medicine pieces, ensuring the quality of traditional Chinese medicines and increasing the income of local farmers.

Guoyitang Pharmaceutical obtained the qualification for the production and labeling of the first batch of traditional Chinese medicine pieces from the State Food and Drug Administration in 2003. The close integration of medicine source bases and traditional Chinese medicine pieces has formed the industrial chain of Guoyitang Pharmaceutical, achieving a win-win situation for social benefits and enterprise development.

The research, development and introduction of drugs are the lifeblood of pharmaceutical companies.

Guoyitang Holdings sincerely invites a backbone R&D team with top-notch academics, leading technology, strong sense of responsibility and sincere unity. They have been engaged in drug research for a long time and have a wide range of research topics. They have good information on new drugs, specialty drugs, and generic drugs. They have rich technical experience and profound professional knowledge. They are experts and scholars who are familiar with the development trends of the domestic and foreign pharmaceutical industries. Among them, full-time R&D personnel 19 (5 senior, 6 deputy senior, 8 intermediate) and 15 part-time medical experts (8 senior, 6 deputy senior, 1 intermediate). To this end, the Beijing Institute of Traditional Chinese Medicine was established with capital injection. It cooperated with the state and professional schools and scientific research institutions in Beijing and Guangzhou to establish close collaborative relationships and formed a research and development team with wide information sources, high professional level, and flexible and effective management. Provide products and technical services to enterprises, specializing in medicinal chemistry, pharmaceutical preparations, pharmaceutical analysis, pharmacology and toxicology, clinical research and other fields. This enables Guoyitang Pharmaceutical to complete practical work such as extraction, separation, purification, preparation and analysis of natural drugs, registration, evaluation of drug effectiveness and safety, and pilot scale-up of natural drugs with high efficiency and high quality. It has reserved a large number of new products of common drugs and special drugs, and obtained exclusive It has 5 patented technologies and successfully registered 99 trademarks of traditional Chinese medicine and health products, laying a technical foundation for the realization of technological enterprise and sustainable development.

Guoyitang Pharmaceutical uses the PM system to integrate the information flow, logistics and capital flow of drugs and health products, and has built a system covering Beijing, Shanghai, Guangdong, Chongqing, Sichuan, Guangxi, Yunnan, Zhejiang, Jiangsu, Regional marketing networks at home and abroad such as Anhui, Hebei, Henan, Shandong, Shanxi, Shaanxi, Liaoning, Jilin, Heilongjiang and Canada have achieved a complementary production and marketing pattern in which production is determined by sales and sales are stabilized by production.

In terms of the capital market, Guoyitang has continued to develop. After continuous leap-forward development in production, research and development, sales, and services, in order to consolidate the company's operating results and seize development opportunities, the shareholders' meeting decided to: Guoyitang will become stronger and bigger, increase its grade and scale, and achieve the mid-term goal of building a backbone pharmaceutical production enterprise. In accordance with the relevant provisions of the "Company Law" and the "Securities Law", in April 2004, three long-term firms were entrusted with matters such as capital verification audit, legal authentication, market entry guidance, sponsorship and underwriting in the three stages of restructuring and reorganization, issuance guidance, and stock listing. Reputable professional securities, legal, and auditing institutions serve as intermediaries to comprehensively implement the restructuring and construction of modern enterprise systems. After one and a half years of systematic work, in October 2005, the Guangdong Provincial Government approved the overall change of Guangdong Guoyitang Pharmaceutical Co., Ltd. into Guangdong Guoyitang Pharmaceutical Co., Ltd., and completed the joint-stock company registration procedures with the Provincial Administration for Industry and Commerce. At this point, Guoyitang Pharmaceutical's corporate restructuring procedures have been completed, and it entered pre-issuance counseling in 2006. The company strives to publicly issue the shares of Guoyitang Pharmaceutical as soon as possible, enter the national capital market, and complete the transformation and construction of a modern enterprise system.

When stocks are listed and issued and integrated into the capital market, it is the day when strategic development begins.